Hangzhou Bio‑Sincerity Secures NMPA Approval for BIOS‑0625 Tablet – First‑in‑Class Ulcerative Colitis Therapy
Hangzhou Bio‑Sincerity Co., Ltd. (SHE: 301096) announced today that its BIOS‑0625 tablet, a Class 1 small‑molecule...
CanSinoBIO Licenses ISL‑3C‑LNP Platform to PanRu Biotech – $100 M+ Deal to Accelerate mRNA Cancer Vaccines
CanSino Biologics Inc. (HKG: 6185) announced today a licensing agreement with PanRu Biotechnology (Tianjin) Co.,...
Eisai China and Beckman Coulter Launch Alzheimer’s Blood‑Test Collaboration in Mainland China
Eisai China Holdings (TYO: 4523) and Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. today signed...
Gilead Sciences’ Tro Delvy Fails to Meet Primary Endpoint in ASCENT‑07 Metastatic Breast Cancer Trial
Gilead Sciences Inc. (NASDAQ: GILD) today disclosed that the Phase III ASCENT‑07 study, which compared Trodelvy...
Insilico Medicine & Eli Lilly Forge Strategic AI‑Driven Drug Discovery Alliance
Insilico Medicine, a leader in artificial‑intelligence‑powered drug discovery, today announced a strategic collaboration with Eli Lilly (NYSE:...
DeliNova Raises Nearly RMB 60 Million in Seed & Angel Financing for In‑Vivo CAR‑T Platform
Nantong DeliNova Therapeutics Co., Ltd. announced today the successful closing of a seed‑stage financing round...
Organon Acquires JADA System from Laborie for USD 465 Million
Organon Inc. (NYSE: OGN) announced today that it has entered into an agreement with Laborie...
HBM Holdings and Evinova Form AI‑Powered Biologic Therapy Collaboration
HBM Holdings Limited (HKG: 2142) and Evinova, an independent health‑tech arm of the AstraZeneca Group,...
Jiangsu Hengrui Pharmaceuticals Announces HRS‑2430 Injection Approval for Clinical Trials
China‑listed Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced today that its novel intravenous...
National Health Commission’s Negative Behavior List for Medical Staff Internet‑Based Health Science Popularization (Trial)
The National Health Commission (NHC) announced on 7 November 2025 a “Negative Behavior List for Medical Staff...
Novo Nordisk Rules Out Higher Bid for Metsera as Pfizer Seals $86.25 per Share Deal
Novo Nordisk A/S (NYSE: NVO) confirmed today that it will not pursue an increased offer...
Aureka Biotechnologies Closes Multi‑Million‑Dollar Series A – Generative Antibody Platform Gains 5Y Capital & Qiming Backing
Aureka Biotechnologies, a pioneer in generative antibody drug development, announced today the successful close of...
Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion
China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s...
Shanghai‑Boehringer Ingelheim MOU Launches Stroke Prevention Initiative – Strengthening China Health 2030
During the 8th China International Import Expo (CIIE), the Shanghai Medical Association (SMA) and Boehringer Ingelheim...
Boehringer Ingelheim Taps Beijing Friendship Hospital for MASH Trials – Expands China Key Initiative
Boehringer Ingelheim announced at the 8th China International Import Expo (CIIE) that it has signed...
Zai Lab Q3 2025 Revenue Up 13% YoY to $115.4 M, Led by Nuzyra and Xacduo; Zejula Slows
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) released its third‑quarter 2025 financial results, reporting total...
Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders
In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...
NHSA Pilot AI Review Accelerates Full‑Process Medical Insurance Assessment in 7 Chinese Provinces
The National Healthcare Security Administration (NHSA) has announced a three‑phase, AI‑powered review pilot covering Beijing,...
US FDA’s CNPV Fast‑Track Program Expands to 15 Drugs, Cutting Review Time to Months
The Commissioner’s National Priority Voucher (CNPV) pilot has just added 15 therapies to its two‑batch...